$3.15
+0.09 (+2.94%)
Open$3.10
Previous Close$3.06
Day High$3.19
Day Low$3.05
52W High$16.00
52W Low$2.66
Volume—
Avg Volume274.7K
Market Cap73.92M
P/E Ratio—
EPS$-2.41
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+917.1% upside
Current
$3.15
$3.15
Target
$32.04
$32.04
$22.50
$32.04 avg
$35.39
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 32.29M | 31.67M | 27.66M |
| Net Income | 4.35M | 5.71M | 3.74M |
| Profit Margin | 13.5% | 18.0% | 13.5% |
| EBITDA | 8.33M | 8.25M | 7.51M |
| Free Cash Flow | 3.02M | 4.79M | 4.27M |
| Rev Growth | +12.6% | +22.6% | -0.7% |
| Debt/Equity | 0.19 | 0.18 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |